Design and development of co-crystals of paracetamol and diclofenac and its characterization

Authors

  • Supriya Khatal Department of Pharmaceutics, PDEA’s Shankarrao Ursal College of Pharmaceutical Sciences and Research Centre, Kharadi-14
  • Pallavi Dhekale
  • Tejaswini Kande Department of Pharmaceutical Chemistry, PDEA’s Shankarrao Ursal College of Pharmaceutical Sciences and Research Centre, Kharadi-14

DOI:

https://doi.org/10.61096/ijpar.v8.iss4.2019.657-662

Keywords:

Paracetamol, Diclofenac, Solvent evaporation, Solution co-crystallization, Characterization.

Abstract

Paracetamol is a class III drug which has limited permeability and High solubility, Diclofenac is a class II drug which has High permeability and Low solubility, for overcome this problems co-crystallization method is used.  Co-crystallization is the process to enhance the physical properties of drug molecule especially the solubility. Paracetamol is analgesic and Diclofenac belongs to anti-inflammatory drug (NSAID). Category they are combined for use in tablet formulation. Co-crystallization was used to combine two drugs in single solid phase and thus to achieve new approach for combination therapy. Using the new approach co-crystals of Diclofenac with Paracetamol was prepared. Co-crystallization of two drugs was carried out by using solvent evaporation and solution co-crystallization method. The saturation solubility was done to evaluate the solubility of co-crystals. Dissolution properties were determined and compared with the marketed tablet formulation. The prepared co-crystals have shown several times faster release than marketed tablet and optimized co-crystals were characterized by using FTIR, Dissolution study.

Downloads

Published

2022-09-27

How to Cite

Supriya Khatal, Pallavi Dhekale, & Tejaswini Kande. (2022). Design and development of co-crystals of paracetamol and diclofenac and its characterization. IJPAR JOURNAL, 8(4), 657–662. https://doi.org/10.61096/ijpar.v8.iss4.2019.657-662